B cell activating factor (BAFF) levels are associated with failed remission after 12 months of treatment with benralizumab and mepolizumab in severe asthma.
- DOI
- 10.1186/s12931-026-03500-0
- Published
- 2026 Apr 2
- Container
- Respiratory research
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12931-026-03500-0,
title = {B cell activating factor (BAFF) levels are associated with failed remission after 12 months of treatment with benralizumab and mepolizumab in severe asthma.},
author = {Fischer BC and Drick N and Liu B and Riemann L and Habener A and DeLuca D and Dittrich AM and Hoeper MM and Suhling H and Hansen G and Grychtol R},
year = {2026},
journal = {Respiratory research},
doi = {10.1186/s12931-026-03500-0},
url = {https://doi.org/10.1186/s12931-026-03500-0}
}RIS
TY - JOUR TI - B cell activating factor (BAFF) levels are associated with failed remission after 12 months of treatment with benralizumab and mepolizumab in severe asthma. AU - Fischer BC AU - Drick N AU - Liu B AU - Riemann L AU - Habener A AU - DeLuca D AU - Dittrich AM AU - Hoeper MM AU - Suhling H AU - Hansen G AU - Grychtol R PY - 2026 JO - Respiratory research DO - 10.1186/s12931-026-03500-0 UR - https://doi.org/10.1186/s12931-026-03500-0 ER -
APA
BC, F., N, D., B, L., L, R., A, H., D, D., AM, D., MM, H., H, S., G, H., & R, G. (2026). B cell activating factor (BAFF) levels are associated with failed remission after 12 months of treatment with benralizumab and mepolizumab in severe asthma.. Respiratory research. https://doi.org/10.1186/s12931-026-03500-0
Source records
- pubmed · retrieved 2026-09-25T22:23:05.349Z